EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Avidity Biosciences's Enterprise Value is $1,914.56 Mil.
Avidity Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-143.80 Mil. Therefore, Avidity Biosciences's EV-to-FCF for today is -13.31.
The historical rank and industry rank for Avidity Biosciences's EV-to-FCF or its related term are showing as below:
RNA'
s EV-to-FCF Range Over the Past 10 Years
Min: -328.72 Med: -4.61 Max: 5.73
Current: -13.31
During the past 6 years, the highest EV-to-FCF of Avidity Biosciences was 5.73. The lowest was -328.72. And the median was -4.61.
RNA's EV-to-FCF is ranked worse than 100% of 379
companies
in the Biotechnology industry
Industry Median: 8.34
vs RNA: -13.31
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Avidity Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Avidity Biosciences's EV-to-FCF
For the Biotechnology subindustry, Avidity Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avidity Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avidity Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Avidity Biosciences's EV-to-FCF falls into.
Avidity Biosciences's current Enterprise Value is $1,914.56 Mil.
Avidity Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Avidity Biosciences's PE Ratio for today is calculated as:
Avidity Biosciences's share price for today is $29.50.
Avidity Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Avidity Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Avidity Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Avidity Biosciences (Avidity Biosciences) Business Description
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RNA has been successfully added to your 